サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1577547

アンジオテンシン変換酵素（ACE）阻害薬の世界市場

Angiotensin Converting Enzyme (ACE) Inhibitors

出版日
ページ情報
英文 169 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.85円
アンジオテンシン変換酵素（ACE）阻害薬の世界市場
出版日: 2024年10月25日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 169 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

アンジオテンシン変換酵素（ACE）阻害薬の世界市場は2030年までに35億米ドルに到達

2023年に28億米ドルと推定されるアンジオテンシン変換酵素（ACE）阻害薬の世界市場は、分析期間2023-2030年にCAGR 3.7%で成長し、2030年には35億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである高血圧治療は、CAGR 4.1%を記録し、分析期間終了時には18億米ドルに達すると予測されます。心不全治療分野の成長率は、分析期間中CAGR 3.5%と推定されます。

米国市場は7億5,160万米ドルと推定、中国はCAGR7.0％で成長予測

米国のアンジオテンシン変換酵素（ACE）阻害薬市場は、2023年に7億5,160万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに7億4,450万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは7.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と2.8%と予測されています。欧州では、ドイツがCAGR 2.0%で成長すると予測されています。

世界のアンジオテンシン変換酵素（ACE）阻害薬市場- 主要動向と促進要因のまとめ

心血管疾患管理においてACE阻害薬が重要な理由とは？

アンジオテンシン変換酵素（ACE）阻害薬は心血管疾患、特に高血圧と心不全の治療の要です。これらの薬剤は、アンジオテンシンIを血管を狭める物質であるアンジオテンシンIIに変換する酵素を阻害することによって作用します。血管を弛緩させ血圧を下げることで、ACE阻害薬は心臓発作、脳卒中、その他の心血管イベントのリスクを低下させる。ACE阻害薬は、高血圧やその他の心血管疾患を有する患者の第一選択治療薬として処方されることが多く、より包括的な管理のために利尿薬やカルシウム拮抗薬などの他の薬剤と併用されることもあります。ACE阻害薬は、患者の予後を改善し、高リスク患者の死亡率を低下させる上で重要な役割を果たしています。

ACE阻害薬市場の主要セグメントは？

一般的な薬剤クラス別には、エナラプリル、リシノプリル、ラミプリルなどがあり、それぞれ患者固有のニーズや医師の嗜好に基づいて使用されます。ACE阻害薬の用途は、主に高血圧、心不全、慢性腎臓病の治療に重点を置いており、糖尿病患者の心血管合併症の予防にも使用されています。ACE阻害剤の流通経路には、病院、小売薬局、オンラインプラットフォームなどがあります。市場は、心血管疾患が蔓延している北米や欧州などの先進地域に大きく集中しているが、アジア太平洋地域の新興市場は、ヘルスケアへのアクセスの向上と心血管疾患率の上昇により、急速な成長を遂げています。

技術革新はACE阻害剤市場にどのような影響を与えているか？

ドラッグの製剤化とデリバリーにおける技術の進歩は、ACE阻害薬の有効性と患者のコンプライアンスを向上させています。徐放性製剤は、より便利な投与スケジュールを可能にし、患者の治療レジメンへのアドヒアランスを向上させます。さらに、個別化医療の革新により、ヘルスケアプロバイダーは遺伝的要因に基づいてACE阻害薬治療をカスタマイズできるようになり、より効果的で的を絞った治療が可能になりつつあります。また臨床試験では、ACE阻害薬と他の心血管系治療薬との新たな併用療法が検討されており、治療成績の向上が期待されています。このような開発により、ACE阻害薬はより幅広い患者、特に複雑な疾患や合併症を持つ患者にとって、より利用しやすく効果的な治療薬となりつつあります。

ACE阻害薬市場の成長を促す要因とは？

ACE阻害薬市場の成長は、高血圧や心血管疾患の有病率の上昇、ドラッグデリバリー技術の進歩、予防医療への関心の高まりなど、いくつかの要因によってもたらされます。世界人口の高齢化と慢性疾患の増加に伴い、効果的な心血管治療に対する需要が拡大しています。高血圧管理に対する意識の高まりや、手頃な価格のACE阻害薬ジェネリック医薬品の入手可能性も、市場の成長に寄与しています。さらに、新薬の組み合わせや個別化医療のアプローチに関する継続的な調査が市場に新たな機会をもたらし、市場拡大をさらに後押ししています。

調査対象企業の例（注目の25社）

  • Accord Healthcare, Inc.
  • Apotex, Inc.
  • AstraZeneca Plc
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Pharmanovia
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP24556

Global Angiotensin Converting Enzyme (ACE) Inhibitors Market to Reach US$3.5 Billion by 2030

The global market for Angiotensin Converting Enzyme (ACE) Inhibitors estimated at US$2.8 Billion in the year 2023, is expected to reach US$3.5 Billion by 2030, growing at a CAGR of 3.7% over the analysis period 2023-2030. Hypertension Treatment, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Heart Failure Treatment segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$751.6 Million While China is Forecast to Grow at 7.0% CAGR

The Angiotensin Converting Enzyme (ACE) Inhibitors market in the U.S. is estimated at US$751.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$744.5 Million by the year 2030 trailing a CAGR of 7.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Angiotensin Converting Enzyme (ACE) Inhibitors Market - Key Trends and Drivers Summarized

Why Are ACE Inhibitors Important in Cardiovascular Disease Management?

Angiotensin Converting Enzyme (ACE) inhibitors are a cornerstone in the treatment of cardiovascular diseases, particularly hypertension and heart failure. These medications work by inhibiting the enzyme that converts angiotensin I to angiotensin II, a substance that narrows blood vessels. By relaxing blood vessels and reducing blood pressure, ACE inhibitors lower the risk of heart attacks, strokes, and other cardiovascular events. They are often prescribed as a first-line treatment for patients with high blood pressure or other cardiovascular conditions and are sometimes combined with other medications such as diuretics or calcium channel blockers for more comprehensive management. ACE inhibitors play a critical role in improving patient outcomes and reducing mortality in high-risk individuals.

What Are the Key Segments in the ACE Inhibitors Market?

Common drug classes include enalapril, lisinopril, and ramipril, each of which is used based on patient-specific needs and physician preferences. Applications of ACE inhibitors primarily focus on treating hypertension, heart failure, and chronic kidney disease, with additional uses in preventing cardiovascular complications in diabetic patients. Distribution channels for ACE inhibitors include hospitals, retail pharmacies, and online platforms. The market is heavily concentrated in developed regions such as North America and Europe, where cardiovascular diseases are prevalent, but emerging markets in Asia-Pacific are experiencing rapid growth due to increased healthcare access and rising cardiovascular disease rates.

How Are Technological Innovations Influencing the ACE Inhibitors Market?

Technological advancements in drug formulation and delivery are enhancing the efficacy and patient compliance of ACE inhibitors. Extended-release formulations allow for more convenient dosing schedules, improving patient adherence to treatment regimens. Additionally, innovations in personalized medicine are enabling healthcare providers to tailor ACE inhibitor therapies based on genetic factors, leading to more effective and targeted treatments. Clinical trials are also exploring new combinations of ACE inhibitors with other cardiovascular drugs, offering potential for enhanced therapeutic outcomes. These developments are making ACE inhibitors more accessible and effective for a wider range of patients, particularly those with complex or coexisting conditions.

What Factors Are Driving Growth in the ACE Inhibitors Market?

The growth in the ACE inhibitors market is driven by several factors, including the rising prevalence of hypertension and cardiovascular diseases, advancements in drug delivery technologies, and the increasing focus on preventive healthcare. As the global population ages and the incidence of chronic diseases rises, the demand for effective cardiovascular treatments is expanding. The growing awareness of hypertension management and the availability of affordable generic ACE inhibitors are also contributing to market growth. Additionally, ongoing research into new drug combinations and personalized medicine approaches is opening up new opportunities in the market, further driving its expansion.

Select Competitors (Total 25 Featured) -

  • Accord Healthcare, Inc.
  • Apotex, Inc.
  • AstraZeneca Plc
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Ltd.
  • Novartis AG
  • Pfizer, Inc.
  • Pharmanovia
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Angiotensin Converting Enzyme (ACE) Inhibitors - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Hypertension and Cardiovascular Diseases Spurs Demand for ACE Inhibitors
    • Technological Innovations in Drug Formulation Strengthen Business Case for Advanced ACE Inhibitors
    • Increasing Focus on Managing Hypertension Expands Addressable Market for ACE Inhibitors
    • Surge in Aging Population Propels Demand for Cardiovascular Treatments, Including ACE Inhibitors
    • Growing Use of ACE Inhibitors in Combination Therapies Expands Treatment Options
    • Technological Advancements in Drug Delivery Systems Enhance Patient Compliance for ACE Inhibitors
    • Rising Awareness of Preventive Healthcare Drives Adoption of ACE Inhibitors for Hypertension Management
    • Technological Innovations in Personalized Medicine Propel Growth in Cardiovascular Drug Market
    • Rising Importance of Preventing Cardiovascular Events Drives Demand for ACE Inhibitors
    • Technological Advancements in Pharmacogenomics Enhance ACE Inhibitor Efficacy
    • Growing Focus on Reducing Hospitalizations Due to Cardiovascular Diseases Propels Market Growth
    • Increasing Focus on Lifestyle Management and Preventive Care Sustains Demand for ACE Inhibitors
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Angiotensin Converting Enzyme (ACE) Inhibitors Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hypertension Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hypertension Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hypertension Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Heart Failure Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Heart Failure Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Heart Failure Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chronic Kidney Disorders Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chronic Kidney Disorders Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Chronic Kidney Disorders Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Treatment Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Treatment Areas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Treatment Areas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • JAPAN
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • CHINA
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • EUROPE
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • FRANCE
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • GERMANY
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • INDIA
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030
  • AFRICA
    • Angiotensin Converting Enzyme (ACE) Inhibitors Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for Angiotensin Converting Enzyme (ACE) Inhibitors by Treatment Area - Percentage Breakdown of Value Sales for Hypertension Treatment, Heart Failure Treatment, Chronic Kidney Disorders Treatment and Other Treatment Areas for the Years 2014, 2024 & 2030

IV. COMPETITION